Anika Therapeutics, Inc. (ANIK) SEC Filings & Earnings Calls

Regulatory approval uncertainty for Hyalofast and Cingal; 2027 revenue guidance revised to exclude Hyalofast

“Given the timing uncertainty that remains in our regulatory review process... our 2027 Commercial Channel revenue guidance no longer includes revenue associated with Hyalofast.” · word for word

Pricing pressure in OEM channel

“$6.1 million increase in sales volume, offset by a $2.9 million decrease due to lower pricing.” · word for word

Dependence on J&J MedTech

“The increase in revenue was driven by higher sales activity with our Original Equipment Manufacturer, or OEM Channel partners, primarily J&J MedTech” · word for word

Regulatory uncertainty for Cingal and Hyalofast

“We have been actively engaging with FDA, on next steps for U.S. regulatory approval. ... the timing of any potential NDA submission or regulatory approval remains subject to the completion of these development and regulatory requirements.” · word for word

Covenant restrictions and secured debt; leverage and interest coverage ratio requirements

“The covenants include restrictions governing our leverage ratio and interest coverage ratio” · word for word

Potential dilution from increased share reserves for equity plans

“350,000 shares added to incentive plan; 200,000 shares added to ESPP”

Restructuring execution risk

“Severance costs of $1.6 million associated with restructuring strategy.”

Cash burn acceleration

“Cash used in operating activities increased to $4.9 million from $0.1 million.”

Dependence on FDA approval for key products

“Cingal and Hyalofast are not yet approved in the U.S.; delays could impact growth.”

Board resignations of two directors may indicate governance changes.

“William R. Jellison and Glenn R. Larsen resigned from the Board, effective at the 2026 annual meeting.”

One-time severance costs of $4.9M impacted operating expenses.

“Total operating expenses were $24.5 million, compared to $19.0 million in the prior-year period, primarily reflecting $4.9 million of one-time severance costs.” · word for word

Customer Concentration Risk

“Our largest customer, J&J MedTech, represented 50% of total revenues for the year ended December 31, 2025.”

OEM Channel Pricing Pressure

“While OEM revenue declined due to anticipated U.S. pricing dynamics for Monovisc and Orthovisc” · word for word

Activist Stockholder Risk

“We have been, and may continue to be, subject to the actions of activist stockholders, which could cause us to incur substantial costs, divert management’s and the board’s attention and resources, and have an adverse effect on our business and stock price.”

Regulatory Approval Risk (Hyalofast, Cingal)

“Continued engagement with the FDA regarding the process to obtain regulatory approval of Hyalofast and Cingal in the United States” · word for word

International Operations Risk

“During 2025, 2024, and 2023, 38%, 31%, and 28%, respectively, of our product sales were to international customers.”

Customer concentration risk

“Our largest customer, J&J MedTech, represented 50% of total revenues for the year ended December 31, 2025.” · word for word

Activist stockholder distraction

“If Caligan, or another activist stockholder, solicits proxies for its candidates or proceeds with other similar types of actions, our business could be adversely affected. Responding to such actions by activist stockholders can be costly and time-consuming, disrupt our operations and divert the attention of management and our board of directors.” · word for word

Divestiture execution risk

“While the divestitures are substantially complete, there may be increased risk with the divestitures of these businesses due to diversion of the attention of management created by the divestiture process, disruptions or other difficulties encountered in the divestiture process, and unforeseen liabilities or unanticipated problems with the businesses being so” · word for word

Loss of senior legal and corporate governance leadership could disrupt operations and strategic initiatives.

“Departure of EVP, General Counsel and Corporate Secretary with transition period ending May 1, 2026.”

CEO transition risk with separation agreement and new CEO compensation package

“CEO transition with separation agreement and new CEO compensation package”

OEM pricing dependency

“Revenue from our OEM Channel product family decreased by 20% and 19% for the three- and nine-month periods ended September 30, 2025, respectively, as compared to the same period in 2024.” · word for word

Hyalofast clinical trial failure

“In July 2025, we received topline results from the study and Hyalofast did not achieve significance on its pre-specified co-primary endpoints for pain and function.” · word for word

Gross margin compression

“Gross margin for the three- and nine-month periods ended September 30, 2025 was 56% and 54%, respectively. Gross margin was 66% for each of the three- and nine-month periods ended September 30, 2024.” · word for word

OEM Channel revenue decline due to lower U.S. pricing for Monovisc and Orthovisc.

“OEM Channel revenue was down 20% in line with expectations. The decline was driven by lower U.S. pricing for Monovisc and Orthovisc.”

Regulatory dependency for Hyalofast PMA approval and Cingal NDA filing.

“Hyalofast PMA third module filed; Cingal NDA filing requires completion of toxicity and bioequivalence studies.”